The coronavirus pandemic has caused global health authorities and agencies to introduce new measures as respective governments respond to growing outbreaks. That includes the NHS which announced today that it will increase its capabilities to test for the coronavirus, which causes the respiratory disease known as COVID-19. Currently, 1,500 tests can be carried out per
Cancer drugs approved in the US by the FDA have an average of 6.5 years to go from the first clinical trial in adults to the first trial in children, according to a study at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. The study was published in the May issue of the European Journal of
EMA has accepted GW Pharmaceuticals’ request to review the MMA (Marketing Authorisation Application) of Epidiolex, or cannibidiol. The treatment is currently used on patients who suffer from seizures linked to Lennox-Gastaut syndrome and Dravet syndrome. GW Pharmaceuticals first submitted Epidiolex for review in December 2017. The successful filing of the MAA of the drug follows
Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from
In the past few years 3D printing has become the next big trend on the horizon and it has now turned its sights onto the pharmaceutical industry… A few days ago the FDA approved the world’s first 3D printed drug; Aprecia’s Spritam and will be used for treating epilepsy. One of the many benefits of
Nursing home residents over 65 who take certain antipsychotics for dementia are at an increased risk of death, according to a recent study by the Harvard Medical School involving 75,445 patients. In a paper published on bmj.com, the study, which was the largest ever undertaken among US nursing home residents, looked at risks of mortality
Eisai has received mixed news this week, after news that Dacogen, Eisai and Astex Pharmaceuticals’ drug to treat a type of leukaemia, has been rejected by an independent advisory panel to the regulator in the USA. The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee voted 10 to 3 that statistics in Eisai’s
